Eterna Therapeutics (ERNA) Competitors $0.17 -0.05 (-22.93%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.18 +0.01 (+3.21%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERNA vs. FRTX, OGEN, NLSP, SNOA, ENSC, ONVO, PWUP, KZIA, CMND, and CPHIShould you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Fresh Tracks Therapeutics (FRTX), Oragenics (OGEN), NLS Pharmaceutics (NLSP), Sonoma Pharmaceuticals (SNOA), Ensysce Biosciences (ENSC), Organovo (ONVO), PowerUp Acquisition (PWUP), Kazia Therapeutics (KZIA), Clearmind Medicine (CMND), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry. Eterna Therapeutics vs. Fresh Tracks Therapeutics Oragenics NLS Pharmaceutics Sonoma Pharmaceuticals Ensysce Biosciences Organovo PowerUp Acquisition Kazia Therapeutics Clearmind Medicine China Pharma Fresh Tracks Therapeutics (NASDAQ:FRTX) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation. Do institutionals & insiders have more ownership in FRTX or ERNA? 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are owned by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are owned by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, FRTX or ERNA? Fresh Tracks Therapeutics has higher revenue and earnings than Eterna Therapeutics. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFresh Tracks Therapeutics$10.06M0.56-$5.69M-$1.41-0.66Eterna Therapeutics$582K1.62-$21.67M-$8.31-0.02 Does the MarketBeat Community prefer FRTX or ERNA? Fresh Tracks Therapeutics and Eterna Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformFresh Tracks TherapeuticsOutperform VotesNo VotesUnderperform Votes1100.00% Eterna TherapeuticsN/AN/A Does the media favor FRTX or ERNA? In the previous week, Eterna Therapeutics had 3 more articles in the media than Fresh Tracks Therapeutics. MarketBeat recorded 3 mentions for Eterna Therapeutics and 0 mentions for Fresh Tracks Therapeutics. Eterna Therapeutics' average media sentiment score of 0.18 beat Fresh Tracks Therapeutics' score of 0.00 indicating that Eterna Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Fresh Tracks Therapeutics Neutral Eterna Therapeutics Neutral Which has more volatility & risk, FRTX or ERNA? Fresh Tracks Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.47, meaning that its share price is 347% more volatile than the S&P 500. Is FRTX or ERNA more profitable? Fresh Tracks Therapeutics has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%. Company Net Margins Return on Equity Return on Assets Fresh Tracks TherapeuticsN/A N/A N/A Eterna Therapeutics -7,513.88%N/A -117.48% SummaryEterna Therapeutics beats Fresh Tracks Therapeutics on 7 of the 12 factors compared between the two stocks. Remove Ads Get Eterna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERNA vs. The Competition Export to ExcelMetricEterna TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$944,000.00$6.91B$5.63B$7.83BDividend YieldN/A2.79%5.33%4.02%P/E Ratio-0.027.2923.6818.75Price / Sales1.62218.91383.9790.87Price / CashN/A65.6738.1734.64Price / Book0.436.386.894.23Net Income-$21.67M$142.34M$3.20B$247.47M7 Day Performance-32.92%-5.83%-3.57%-3.56%1 Month Performance-42.61%-7.55%1.50%-5.81%1 Year Performance-92.73%-11.06%9.32%-0.96% Eterna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERNAEterna Therapeutics0.9929 of 5 stars$0.17-22.9%N/A-92.7%$944,000.00$582,000.00-0.0210FRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+3.4%$5.59M$10.06M-0.6620OGENOragenicsN/A$0.26flatN/A-85.0%$5.58M$40,000.00-0.045Analyst ForecastNLSPNLS PharmaceuticsN/A$1.51flatN/A+622.2%$5.43MN/A0.006Short Interest ↓SNOASonoma Pharmaceuticals0.3682 of 5 stars$3.23-7.2%N/A+1,349.2%$5.22M$13.97M-0.80180ENSCEnsysce Biosciences1.0167 of 5 stars$3.65+5.8%N/A-72.6%$5.13M$2.23M-0.1310Short Interest ↓ONVOOrganovo0.9922 of 5 stars$2.99-4.8%N/A-80.5%$5.09M$122,000.00-3.5220PWUPPowerUp AcquisitionN/A$0.63-8.4%N/A-94.2%$4.90MN/A0.00N/AHigh Trading VolumeKZIAKazia Therapeutics2.8709 of 5 stars$0.95-2.6%$11.50+1,110.4%-71.6%$4.79M$2.31M0.0012Short Interest ↑News CoverageGap UpCMNDClearmind Medicine0.9667 of 5 stars$1.10-1.8%N/A-7.0%$4.69MN/A-0.59N/AShort Interest ↓Gap UpCPHIChina PharmaN/A$0.24+3.1%N/A-26.0%$4.68M$5.54M0.00250Analyst Forecast Remove Ads Related Companies and Tools Related Companies FRTX Alternatives OGEN Alternatives NLSP Alternatives SNOA Alternatives ENSC Alternatives ONVO Alternatives PWUP Alternatives KZIA Alternatives CMND Alternatives CPHI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERNA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eterna Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eterna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
